FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122079295> ?p ?o ?g. }

• W3122079295 endingPage "1908" @default.
• W3122079295 startingPage "1896" @default.
• W3122079295 abstract "MYCN is amplified in 20% to 25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a large percent of pediatric cancer-related deaths. Therapy improvements for this subtype of cancer are a high priority. Here we uncover a MYCN-dependent therapeutic vulnerability in neuroblastoma. Namely, amplified MYCN rewires the cell through expression of key receptors, ultimately enhancing iron influx through increased expression of the iron import transferrin receptor 1. Accumulating iron causes reactive oxygen species (ROS) production, and MYCN-amplified neuroblastomas show enhanced reliance on the system Xc- cystine/glutamate antiporter for ROS detoxification through increased transcription of this receptor. This dependence creates a marked vulnerability to targeting the system Xc-/glutathione (GSH) pathway with ferroptosis inducers. This reliance can be exploited through therapy with FDA-approved rheumatoid arthritis drugs sulfasalazine (SAS) and auranofin: in MYCN-amplified, patient-derived xenograft models, both therapies blocked growth and induced ferroptosis. SAS and auranofin activity was largely mitigated by the ferroptosis inhibitor ferrostatin-1, antioxidants like N-acetyl-L-cysteine, or by the iron scavenger deferoxamine (DFO). DFO reduced auranofin-induced ROS, further linking increased iron capture in MYCN-amplified neuroblastoma to a therapeutic vulnerability to ROS-inducing drugs. These data uncover an oncogene vulnerability to ferroptosis caused by increased iron accumulation and subsequent reliance on the system Xc-/GSH pathway. SIGNIFICANCE: This study shows how MYCN increases intracellular iron levels and subsequent GSH pathway activity and demonstrates the antitumor activity of FDA-approved SAS and auranofin in patient-derived xenograft models of MYCN-amplified neuroblastoma." @default.
• W3122079295 created "2021-02-01" @default.
• W3122079295 creator A5001008344 @default.
• W3122079295 creator A5005679100 @default.
• W3122079295 creator A5008972260 @default.
• W3122079295 creator A5015077321 @default.
• W3122079295 creator A5020741942 @default.
• W3122079295 creator A5022350978 @default.
• W3122079295 creator A5026990509 @default.
• W3122079295 creator A5037442217 @default.
• W3122079295 creator A5043402436 @default.
• W3122079295 creator A5045243433 @default.
• W3122079295 creator A5049700214 @default.
• W3122079295 creator A5050946845 @default.
• W3122079295 creator A5054248424 @default.
• W3122079295 creator A5056470952 @default.
• W3122079295 creator A5065885586 @default.
• W3122079295 creator A5071720546 @default.
• W3122079295 creator A5071844087 @default.
• W3122079295 creator A5083047539 @default.
• W3122079295 creator A5089402878 @default.
• W3122079295 date "2021-01-22" @default.
• W3122079295 modified "2023-10-16" @default.
• W3122079295 title "<i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis" @default.
• W3122079295 cites W123468314 @default.
• W3122079295 cites W1891848729 @default.
• W3122079295 cites W1973249583 @default.
• W3122079295 cites W1978772332 @default.
• W3122079295 cites W1996311090 @default.
• W3122079295 cites W1996390826 @default.
• W3122079295 cites W1997183854 @default.
• W3122079295 cites W2002490399 @default.
• W3122079295 cites W2035898183 @default.
• W3122079295 cites W2054662394 @default.
• W3122079295 cites W2057632732 @default.
• W3122079295 cites W2062107099 @default.
• W3122079295 cites W2090880672 @default.
• W3122079295 cites W2098282574 @default.
• W3122079295 cites W2110508238 @default.
• W3122079295 cites W2119081952 @default.
• W3122079295 cites W2120269671 @default.
• W3122079295 cites W2137749199 @default.
• W3122079295 cites W2138809862 @default.
• W3122079295 cites W2150633938 @default.
• W3122079295 cites W2152855697 @default.
• W3122079295 cites W2156683768 @default.
• W3122079295 cites W2289153964 @default.
• W3122079295 cites W2327686392 @default.
• W3122079295 cites W2513841008 @default.
• W3122079295 cites W2604049161 @default.
• W3122079295 cites W2727828415 @default.
• W3122079295 cites W2741508285 @default.
• W3122079295 cites W2765658403 @default.
• W3122079295 cites W2767055857 @default.
• W3122079295 cites W2777333782 @default.
• W3122079295 cites W2788562722 @default.
• W3122079295 cites W2793635377 @default.
• W3122079295 cites W2794248491 @default.
• W3122079295 cites W2803410634 @default.
• W3122079295 cites W2806219344 @default.
• W3122079295 cites W2888091897 @default.
• W3122079295 cites W2890668604 @default.
• W3122079295 cites W2900358413 @default.
• W3122079295 cites W2902229746 @default.
• W3122079295 cites W2912617835 @default.
• W3122079295 cites W2922166085 @default.
• W3122079295 cites W2924471609 @default.
• W3122079295 cites W2932111434 @default.
• W3122079295 cites W2979398595 @default.
• W3122079295 cites W2988148590 @default.
• W3122079295 cites W3011868091 @default.
• W3122079295 cites W3045511770 @default.
• W3122079295 cites W4233526312 @default.
• W3122079295 cites W4256298802 @default.
• W3122079295 doi "https://doi.org/10.1158/0008-5472.can-20-1641" @default.
• W3122079295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33483374" @default.
• W3122079295 hasPublicationYear "2021" @default.
• W3122079295 type Work @default.
• W3122079295 sameAs 3122079295 @default.
• W3122079295 citedByCount "59" @default.
• W3122079295 countsByYear W31220792952021 @default.
• W3122079295 countsByYear W31220792952022 @default.
• W3122079295 countsByYear W31220792952023 @default.
• W3122079295 crossrefType "journal-article" @default.
• W3122079295 hasAuthorship W3122079295A5001008344 @default.
• W3122079295 hasAuthorship W3122079295A5005679100 @default.
• W3122079295 hasAuthorship W3122079295A5008972260 @default.
• W3122079295 hasAuthorship W3122079295A5015077321 @default.
• W3122079295 hasAuthorship W3122079295A5020741942 @default.
• W3122079295 hasAuthorship W3122079295A5022350978 @default.
• W3122079295 hasAuthorship W3122079295A5026990509 @default.
• W3122079295 hasAuthorship W3122079295A5037442217 @default.
• W3122079295 hasAuthorship W3122079295A5043402436 @default.
• W3122079295 hasAuthorship W3122079295A5045243433 @default.
• W3122079295 hasAuthorship W3122079295A5049700214 @default.
• W3122079295 hasAuthorship W3122079295A5050946845 @default.
• W3122079295 hasAuthorship W3122079295A5054248424 @default.
• W3122079295 hasAuthorship W3122079295A5056470952 @default.

• next